Good to see the FDA moving on this as we're starting to hear of afib patients with mechanical heart valves getting Pradaxa. Here is the FDA announcement... ISSUE: The U.S. Food and Drug Administration (FDA) is informing health care professionals and the public that the blood thinner (anticoagulant) Pradaxa (dabigatran etexilate mesylate) should not be used …
Read More
StopAfib.org is pleased to unveil the Top Ten Atrial Fibrillation Articles of 2012. There were many topics of interest this year to the atrial fibrillation patient community. As always, the top interest was atrial fibrillation stroke prevention — that included the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for anticoagulants, the HAS-BLED tool …
Read More
Patients with atrial fibrillation are at higher risk of suffering stroke and other complications related to the development of blood clots in their heart. Until 2010, the only oral anticoagulant (blood thinner) to prevent strokes in Afib was warfarin (Coumadin®). Now there are two new oral anticoagulants available in the United States--dabigatran (Pradaxa®) and rivaroxaban …
Read More
StopAfib.org interviews Dr. Daniel Singer of Harvard Medical School. Find more information on this topic, and Dr. Singer, at: http://www.stopafib.org/newsitem.cfm/NEWSID/397 Dr. Singer led a symposium on atrial fibrillation stroke prevention at Boston Atrial Fibrillation Symposium 2012. In this video interview, Dr. Singer shared with StopAfib.org information from that symposium. He provided an update on rivaroxaban …
Read More
In this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium. He provided an update on rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban, and mentioned that all were better than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the …
Read More
StopAfib.org interviews Dr. Elaine Hylek of Boston University. A transcript of this video, as well as additional information about the topics discussed, and Dr. Hylek, can be found at: http://www.stopafib.org/newsitem.cfm/NEWSID/349 In this video interview, Dr. Elaine Hylek of Boston University discusses new anticoagulant drugs for stroke prevention in atrial fibrillation. For many years, warfarin (Coumadin) …
Read More
In follow up to our announcement yesterday of the Top Ten Atrial Fibrillation Videos of 2011, StopAfib.org now unveils the Top Ten Atrial Fibrillation Articles of 2011. Major topics of interest to the atrial fibrillation patient community this year were afib stroke prevention and the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for …
Read More
StopAfib.org has announced the Top Ten Atrial Fibrillation Videos of 2011. Afib stroke prevention again topped the list, with stories about warfarin (Coumadin), alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto), and the CHADS2 and CHA2DS2-VASc scoring tools for determining whether anticoagulants are needed. Other popular topics included sleep apnea, catheter ablation, and maze procedures (surgical …
Read More
As a patient, you probably see lots of hype-filled reports about various drugs. After a drug is approved, there’s an inevitable blitz of negative publicity which often scares people away from important new solutions that could help them. There has been so much news lately about Multaq (dronedarone), the drug designed to provide the benefits …
Read More
The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation. In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed …
Read More